This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
GABRA1 / Gamma-aminobutyric acid receptor subunit alpha-1 · IHC design guide
Design Immunohistochemistry for GABRA1
Plan chromogenic paraffin-section IHC with the catalog antibody (datasheet PA1578). Use high-staining cerebellar synaptic glomeruli and cortical neuropil as reference tissues (HPA tissue IHC), and interpret the pattern alongside GABRA1’s postsynaptic membrane location (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
GABRA1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Postsynaptic membrane (UniProt); neuropil (HPA tissue IHC) | |
| Staining pattern | Selective staining in neuropil and a subset of neurons (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet PA1578) | |
| Positive control | Cerebellum+1 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Regional variation: low neuronal staining in hippocampus and caudate (HPA tissue IHC) | |
| Regulation | No regulator in supplied record (UniProt) | |
| Isoform / epitope | 0 isoforms annotated; extracellular versus cytoplasmic epitope location matters (UniProt) |
Section 1
Recommended GABRA1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by published GABRA1 IHC methods for mouse brain (PMC11421448) and rat hypothalamus (PMC8740267).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet PA1578); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet PA1578); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet PA1578) |
| Primary antibody | Rabbit anti-GABRA1, 0.5-1μg/ml (datasheet PA1578) |
| Primary incubation | Overnight at 4 °C (datasheet PA1578) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet PA1578) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | GABRA1-positive staining in synaptic glomeruli - capsule of cerebellum (HPA tissue IHC: High). HPA tissue profile: Selective expression in neuropil and subset of neurons. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA at pH 8.0 for the catalog antibody (datasheet PA1578). The rat study used high-pressure boiling for retrieval (PMC8740267).
Section 2
What Is the Expected GABRA1 Staining Pattern?
GABRA1 is a membrane receptor subunit concentrated at postsynaptic sites, with four transmembrane segments (UniProt P14867 topology; UniProt P14867 subcellular). In IHC, expect staining in neuropil and a subset of neurons, especially cerebellar synaptic glomeruli and cerebral cortical neuropil (HPA tissue IHC: Enhanced; HPA tissue IHC: High in both sites). HPA calls the tissue pattern Enhanced because staining is consistent with RNA expression (HPA tissue IHC: reliability description).
| Strong staining outlines cerebellar synaptic glomeruli or fills cortical neuropil while nearby structures vary in intensity (HPA tissue IHC: High in both sites). | This matches the reported selective neural pattern (HPA tissue IHC: selective expression in neuropil and a subset of neurons). Assess signal within the named structures instead of requiring every neuronal cell body to stain; UniProt places GABRA1 mainly at GABAergic synapses and at lower concentration on extrasynaptic membrane (UniProt P14867 subcellular). |
| Predominantly nuclear staining appears in a paraffin section, without a convincing neural membrane or neuropil pattern. | Treat this as discordant with the expected IHC distribution, then check controls and morphology before calling it GABRA1 (UniProt P14867 subcellular; HPA tissue IHC: profile). HPA reports nucleoplasm only as an uncertain additional ICC-IF location and cautions that its subcellular summary uses antibodies targeting multiple genes (HPA subcellular: uncertain nucleoplasm; HPA subcellular: caution). |
| Strong, widespread staining appears in glandular or other non-neural cells where the selected HPA reference is negative. | For example, HPA reports adrenal glandular cells and bronchial respiratory epithelial cells as not detected (HPA tissue IHC: adrenal gland; HPA tissue IHC: bronchus). Such staining warrants checks for cross-reactivity or endogenous detection activity; it does not alone prove either cause (general IHC practice). Compare the same cell type and detection system in a negative control. |
| A uniform chromogen haze covers tissue compartments and obscures neuropil boundaries. | A field-wide haze cannot establish the selective pattern reported for GABRA1 (HPA tissue IHC: profile). Consider nonspecific antibody binding, incomplete blocking, or unquenched endogenous activity where the detection chemistry permits it (general IHC practice). Judge specificity by whether the background clears while the expected neural structures remain distinguishable. |
| Cerebellar synaptic glomeruli and cortical neuropil show no convincing staining (HPA tissue IHC: High in both sites). | An absent signal in these known-positive structures makes the run inconclusive (HPA tissue IHC: High in both sites; general IHC practice). Check section integrity, antibody and detection controls, then empirically review the IHC-P conditions used. The supplied sources do not report GABRA1-specific fixation sensitivity, so do not assign the failure to fixation. |
💡Expected GABRA1 appearanceCall a positive result when high signal follows cerebellar synaptic glomeruli or cortical neuropil in the expected neural compartment (HPA tissue IHC: High in both sites; UniProt P14867 subcellular); diffuse nuclear or widespread non-neural staining without that pattern is suspect (HPA subcellular: uncertain nucleoplasm; HPA tissue IHC: profile).
| Tissue and structure selected for scoring | Use cerebellar synaptic glomeruli and cortical neuropil as the clearest supplied positive references (HPA tissue IHC: High in both sites). Hippocampal and caudate neuronal cells are reported at low level, so faint staining there carries less weight than a high-level reference (HPA tissue IHC: Low in hippocampus and caudate). |
| Membrane topology and epitope position | GABRA1 has four transmembrane segments, an extracellular region at residues 28–253, and a cytoplasmic region at 334–421 (UniProt P14867 topology). Epitope location can guide antibody and permeabilisation choices in general IHC/IF practice; the supplied record gives no antibody epitope, so it cannot predict which retrieval condition or access route works. |
| Evidence tied to the antibody and application | Two listed antibodies, HPA055746 and CAB022502, have Enhanced IHC status, while HPA029363 has ICC approval and no listed IHC status (HPA antibodies: validation status). Match any interpretation to the antibody's stated application; the tissue-level Enhanced rating describes agreement between staining and RNA data, not universal performance for every reagent (HPA tissue IHC: reliability description). |
| IF/ICC Q: Is nucleoplasmic signal an expected GABRA1 result? | A: HPA supports plasma membrane as the main ICC-IF location but marks nucleoplasm uncertain, with a multiple-gene antibody caution (HPA subcellular: supported plasma membrane; HPA subcellular: uncertain nucleoplasm; HPA subcellular: caution). Interpret IF/ICC on its own evidence; this IHC section offers no IF protocol option. |
| Situation | Likely cause | Next action |
|---|---|---|
| The known-positive cerebellar or cortical structure is blank. | The run may have failed, or its IHC-P conditions may need empirical adjustment (HPA tissue IHC: High in both sites; general IHC practice). | Confirm the section contains the intended structure, inspect positive and detection controls, and review the antibody's IHC-P instructions and retrieval settings (general IHC practice). Do not infer a GABRA1-specific fixation effect from a blank slide. |
| All tissue compartments show similar brown staining. | Nonspecific binding or detection-system background can hide selective staining (general IHC practice). | Compare a no-primary control, check blocking and antibody concentration, and address endogenous activity appropriate to the detection chemistry (general IHC practice). Reassess whether cerebellar glomeruli or cortical neuropil remain enriched (HPA tissue IHC: High in both sites). |
| Nuclei dominate the stain. | Nuclear dominance conflicts with the principal membrane and synaptic locations (UniProt P14867 subcellular; HPA subcellular: supported plasma membrane). | Check counterstain, no-primary control, and antibody-specific validation before scoring nuclei as positive (general IHC practice). HPA's nucleoplasmic ICC-IF call is uncertain and cannot validate nuclear IHC on its own (HPA subcellular: uncertain nucleoplasm). |
| A reported negative cell type stains as strongly as cortical neuropil. | Cross-reactivity or endogenous detection activity is possible; the slide alone cannot distinguish them (general IHC practice). | Compare a matched no-primary control and verify cell identity and anatomy (general IHC practice). Use the exact HPA cell-type reference, such as adrenal glandular cells reported as not detected, rather than treating an entire organ as uniformly negative (HPA tissue IHC: adrenal gland). |
| Hippocampal or caudate neurons are faint while the positive reference is clear. | Low signal may fit the supplied tissue pattern: HPA rates neuronal cells in both sites low (HPA tissue IHC: Low in hippocampus and caudate). | Score those cells against matched background and the same-run high-level cerebellar or cortical reference (HPA tissue IHC: High in both sites; general IHC practice). Avoid escalating a low-level site into a failed run solely because it is weaker. |
| An ICC-IF image suggests nuclear staining, but IHC shows a neural membrane pattern. | The sources describe different applications; HPA's ICC-IF nucleoplasmic location is uncertain (HPA subcellular: uncertain nucleoplasm; HPA antibodies: validation status). | Keep the IHC call anchored to tissue morphology and IHC evidence (HPA tissue IHC: profile; HPA antibodies: IHC status). Review IF/ICC on its dedicated guide and with its own controls (general IF practice). |
Experiment evidence
IHC & IF images showing GABRA1 staining
PA1578 · IHCAnti-GABA A Receptor alpha 1 antibody, PA1578, IHC(P) IHC(P): Rat Brain Tissue
PA1578 · IHCIHC analysis of GABRA1 using anti-GABRA1 antibody (PA1578). GABRA1 was detected in a paraffin-embedded section of human brain tissue. Heat m
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000022355-GABRA1/tissue/cerebral+cortex#imid_12984283
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000022355-GABRA1/tissue/colon#imid_12975248
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000022355-GABRA1/tissue/liver#imid_12975240
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000022355-GABRA1/tissue/kidney#imid_12975241
HPA · ICC-IF A-549Human Protein Atlas immunofluorescence, A-549, antibody HPA029363; green = GABRA1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-549Human Protein Atlas immunofluorescence, A-549, antibody HPA029363; green = GABRA1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for GABRA1 IHC & IF
🧪Run cerebellum first: synaptic glomeruli capsules should stain (HPA: High in synaptic glomeruli - capsule). Use adipose tissue as the negative tissue (HPA: Not detected in adipocytes); on the cerebellum slide, use cell profiles away from stained glomerular capsules to assess background.
Positive control tissue: Cerebellum (Synaptic glomeruli - capsule, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show GABRA1 in A-549, PC-3, U2OS, with annotated localisation: Plasma membrane (supported) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) control, an isotype control matched to the primary antibody’s host species and immunoglobulin class, and knockout tissue or peptide preabsorption when the relevant material is available (standard IHC practice). Check endogenous peroxidase in blood-containing areas and endogenous biotin if using avidin–biotin detection (standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported in the supplied evidence, and the fixative is unreported in the PA1578 rat-brain IHC(P) caption (caption: fixative not stated). Retrieval dependency is also unreported; optimize antigen retrieval against the positive and negative tissues (HPA: High in cerebellar synaptic glomeruli - capsule; Not detected in adipose adipocytes). The supplied evidence does not establish whether frozen sections or IF are easier than paraffin IHC; dense neuropil can complicate assessment of diffuse background around synaptic staining (standard IHC practice).
HPA tissue IHC evidence for GABRA1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | Synaptic glomeruli - capsule | High | Protein (IHC) | HPA → |
| Cerebral cortex | Neuropil | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced GABRA1 IHC Tips
Troubleshoot GABRA1 staining in paraffin sections by checking retrieval, controls, tissue distribution and membrane localisation before interpreting signal intensity.
What retrieval should I try first when GABRA1 staining is weak?
Start with heat-mediated EDTA retrieval at pH 8.0 for the catalog antibody (datasheet PA1578). Keep heating and cooling conditions consistent across sections, then compare a stained section with a no-primary control on the same run (standard IHC practice). Use cerebral cortex neuropil or cerebellar synaptic glomeruli as positive tissue references when available (HPA: High in these regions). If signal remains weak, test a second retrieval condition on matched sections as a fallback, while keeping detection and exposure to chromogen constant (standard IHC practice). Judge improvement by the expected neuropil pattern, not by stronger staining everywhere (HPA: selective neuropil expression).
Could fixation explain weak or uneven GABRA1 staining?
The selected product caption identifies rat brain IHC in paraffin sections but does not state a fixative (caption PA1578). Target-specific sensitivity to fixation is therefore unknown from the supplied evidence (caption PA1578). Record fixative, fixation duration and processing history for each specimen, and compare sections processed together before changing antibody or detection conditions (standard IHC practice). Check whether weak staining follows section folds, poorly preserved areas or inconsistent tissue thickness, since these can change apparent chromogen intensity (standard IHC practice). Use a well-preserved positive reference section in each run to separate specimen handling from a run-wide staining failure (standard IHC practice).
Where should convincing GABRA1 chromogenic staining appear?
Look for staining associated with neuronal membranes and synapse-rich neuropil (UniProt P14867 localisation; HPA: selective neuropil and neuronal expression). GABRA1 is mainly postsynaptic, with lower-concentration extrasynaptic membrane localisation and an annotated cytoplasmic vesicle membrane location (UniProt P14867 localisation). Cerebellar synaptic glomeruli and cerebral cortex neuropil provide region-specific positive references (HPA: High in these regions). Interpret fine neuropil staining in the context of local anatomy and the counterstain, because individual synapses need not be resolved by routine chromogenic IHC (standard IHC practice). Diffuse nuclear staining alone does not match the supported plasma-membrane location; the reported nucleoplasmic location is uncertain (HPA subcellular).
How does epitope position change the GABRA1 staining workflow?
Confirm the catalog antibody’s immunogen or mapped epitope before interpreting a failed stain; its position is not supplied here (datasheet PA1578: epitope not provided). Mature GABRA1 spans residues 28–456, with a large extracellular region at 28–253 and a cytoplasmic region at 334–421 (UniProt P14867 topology). The precursor has a signal peptide at 1–27 and annotated glycosylation sites at 38 and 138 (UniProt P14867 processing and glycosylation). Those features can guide epitope review, but they do not establish this antibody’s binding site or retrieval response (datasheet PA1578: epitope not provided). No isoforms are annotated in the supplied record, so avoid assigning distinct staining patterns to an unverified isoform (UniProt P14867 isoforms).
How should I investigate GABRA1 by multiplex IF alongside this IHC guide?
Use a neuronal marker in a separate channel to test whether GABRA1 signal falls in the expected cell population and neuropil (HPA: selective expression in neuropil and a subset of neurons). Choose spectrally separated fluorophores and inspect unstained tissue for autofluorescence before assigning a weak GABRA1 signal (standard IF practice). Match permeabilisation to the verified epitope: a cytoplasmic epitope needs membrane access, while an extracellular epitope may need less permeabilisation (UniProt P14867 topology; standard IF practice). Because this antibody’s epitope is unspecified, compare mild permeabilisation conditions without assuming which side it recognizes (datasheet PA1578: epitope not provided). Assess each channel alone before interpreting colocalisation (standard IF practice).
What should I check if brown staining covers the whole section?
Compare the stained slide with no-primary and detection-only controls to locate background introduced by the primary antibody or detection system (standard IHC practice). Check the peroxidase block when using HRP and DAB, and limit chromogen development if the control also turns brown (standard chromogenic IHC practice). Recheck blocking, washes and the working antibody concentration against the catalog instructions; no dilution is supplied in this payload (standard IHC practice; datasheet PA1578: dilution not provided). Genuine GABRA1 tissue staining is selective for neuropil and some neurons, rather than uniform across every structure (HPA: tissue IHC profile). Inspect section edges and damaged areas separately, where nonspecific deposits can accumulate (standard IHC practice).
How can I quantify GABRA1 staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define anatomical regions before scoring, because GABRA1 staining is enriched in neuropil and selected neurons (HPA: tissue IHC profile). For neuronal cell bodies, record percentage positive and intensity, or calculate an H-score from intensity categories 0–3 on a 0–300 scale (standard IHC scoring practice). For neuropil, measure positive area or optical density per mm² within matched regions, using one threshold across the batch (standard image analysis practice). Normalise to the analysed tissue area or relevant neuronal area, and report region, section count and scoring rule (standard IHC practice). Keep retrieval, illumination, counterstain and chromogen development consistent for comparisons (standard IHC practice).
Which patterns support genuine GABRA1 signal rather than artefact?
A convincing pattern follows neuronal membranes or synapse-rich neuropil, particularly cerebral cortex neuropil and cerebellar synaptic glomeruli (UniProt P14867 localisation; HPA: High in these regions). Compare that distribution with a no-primary control and tissue areas reported as not detected, such as adipose tissue adipocytes (HPA: Not detected in adipocytes; standard IHC practice). Treat isolated nuclear staining cautiously: plasma membrane is supported, whereas the additional nucleoplasmic assignment is uncertain (HPA subcellular). Examine section edges, necrotic areas and tissue folds for local deposits before scoring them as positive (standard IHC practice). If staining persists in the no-primary control, investigate endogenous peroxidase or detection reagents before assigning it to GABRA1 (standard chromogenic IHC practice).
Boster reagents
Best GABRA1 / Gamma-aminobutyric acid receptor subunit alpha-1 IHC Antibodies
PA1578 has real paraffin-section IHC images from rat and human brain; the catalog lists human, mouse, and rat reactivity, with no IF data (PA1578 image captions; catalog reactivity and images).
Real IHC data
Anti-GABA A Receptor alpha 1/GABRA1 Antibody ®
Cat # PA1578
PA1578 is listed for IHC and WB, with human, mouse, and rat reactivity (PA1578 catalog applications and reactivity). Its IHC images show rat brain tissue and a paraffin-embedded human brain section (PA1578 image captions).
Which to pick: Choose PA1578 for paraffin-section tissue IHC: its own captions show rat brain and paraffin-embedded human brain, but do not report the fixative (PA1578 image captions). For work across human, mouse, and rat, PA1578 lists all three as reactive; the supplied images document human and rat tissue only (PA1578 catalog reactivity; image captions). No IF/ICC application or image is supplied, so there is no supported IF/ICC pick here (PA1578 catalog applications and images).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P14867 (GBRA1_HUMAN, Gamma-aminobutyric acid receptor subunit alpha-1).
- Human Protein Atlas. GABRA1 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. GABRA1 subcellular location (ICC-IF): Mainly localized to the plasma membrane. In addition localized to the nucleoplasm. Caution: Based on antibodies targeting proteins from multiple genes..
- Human Protein Atlas. GABRA1 antibody validation summary (3 antibodies).
- Midazolam Exerts Sedative Effects by Differentially Modulating Cortical Pyramidal Neurons and PV Interneurons. CNS neuroscience & therapeutics 2026 — PMC13398157.
- Impact of Altered Gut Microbiota on Ketamine-Induced Conditioned Place Preference in Mice. Neuropsychiatric disease and treatment 2024 — PMC11421448.
- An airway-to-brain sensory pathway mediates influenza-induced sickness. Nature 2023 — PMC10033449.
- Mechanisms Underlying the Action of Ziziphi Spinosae Semen in the Treatment of Insomnia: A Study Involving Network Pharmacology and Experimental Validation. Frontiers in pharmacology 2021 — PMC8740267.
- PubMed PMID:2465923 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:2847710 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for GABRA1 (Gamma-aminobutyric acid receptor subunit alpha-1). Expected localisation Postsynaptic membrane (UniProt); neuropil (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet PA1578). Validated IHC antibody: PA1578 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Cerebellum (Synaptic glomeruli - capsule); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet PA1578); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet PA1578); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet PA1578); 8. Primary antibody: Rabbit anti-GABRA1, 0.5-1μg/ml (datasheet PA1578); 9. Primary incubation: Overnight at 4 °C (datasheet PA1578). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Regional variation: low neuronal staining in hippocampus and caudate (HPA tissue IHC); Isoform / epitope: 0 isoforms annotated; extracellular versus cytoplasmic epitope location matters (UniProt); Regulation: No regulator in supplied record (UniProt). Evidence: UniProt P14867, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the plasma membrane. In addition localized to…, Datasheet PA1578, PMC11421448, PMC8740267. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/GABRA1/immunohistochemistry-ihc-guide.